Locoregional therapy with drugs for unresectable liver cancer
Part of Cancer, Digestive system clinical trials.
This study looks at combining local treatments (like radiation or chemo delivered directly to the tumor) with newer drugs that fight cancer by blocking blood vessel growth and boosting the immune system. The goal is to see if this combination can help people whose liver cancer cannot be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years of age or older.
- You have been diagnosed with hepatocellular carcinoma, a type of liver cancer.
- Your cancer is at stage I, II, or IIIA according to the China Liver Cancer staging system.
- A team of specialists has determined that your liver cancer cannot be removed with surgery at this time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether combining different liver-directed treatments with newer cancer drugs can help people with liver cancer who are waiting for a liver transplant. It aims to see if these treatments are safe and helpful for a wider group of patients.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.